Loading...
•
Mar 31, 2020
Nevro Q1 2020 Earnings Report
Nevro's financial performance was impacted by COVID-19, but U.S. revenue increased.
Key Takeaways
Nevro Corp. reported a 6% increase in worldwide revenue for Q1 2020, reaching $87.5 million, despite a negative impact from COVID-19 related cancellations. U.S. revenue increased by 14%, while international revenue decreased by 26%. The company's net loss from operations improved by 45% compared to the prior year period.
Worldwide revenue increased by 6% to $87.5 million, despite COVID-19 impacts.
U.S. revenue increased by 14% to $75.3 million, with trial growth at 7% and permanent implant growth at 12%.
International revenue decreased by 26% to $12.2 million due to COVID-19 restrictions.
Net loss from operations improved by 45% to $23.1 million.
Forward Guidance
Due to the rapidly evolving environment and continued uncertainties resulting from the impact of COVID-19, Nevro withdrew its previously announced annual guidance for 2020 on April 1, 2020. Due to the uncertain scope and duration of the pandemic, and the timing of global economic recovery, the Company cannot, at this time, reliably estimate the future impact on its operations and financial results.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...